<DOC>
	<DOCNO>NCT02150408</DOCNO>
	<brief_summary>Gastro-Entero-Pancreatic tumor ( GEPs ) subset Neuroendocrine tumor ( NETs ) derive primitive gut include digestive bronchial NETs . Historically , gold standard functional exploration `` conventional '' somatostatin receptor scintigraphy ( SRS ) label Indium-111 ( Octreoscan® ) . This reference image complementary Tomography ( CT ) liver MRI . However SRS sensitivity moderate ( 60 % ) , intrinsic detection limit , could delay diagnosis lead inappropriate therapy . The use somatostatin agonist ( DOTATOC , DOTATATE , DOTANOC ) , radiolabeled gallium-68 ( 68Ga ) enables target Somatostatin receptor ( SSTRs ) PET resolution . This improved diagnosis TNE gain sensitivity 20 % compare SRS . Furthermore , patient irradiation image protocol significantly reduce .</brief_summary>
	<brief_title>Evaluation PET-CT Using Somatostatin Agonists Labeled With Gallium68 Neuroendocrine Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>• Age ≥ 18 , Patient one follow situation : suspicion GEP , initial stag nonmetastatic GEP , GEP unknown primary tumor , Restaging GEP justify focus therapeutic approach Reference imaging within last 3 month : multiphasic thoracoabdominal CT scan , liver MRI SRS ( SPECT/CT ) . Pregnant breastfeed woman Other cancer disease GEP grade 3 tumour Non GEP TNE ( paragangliome , medullar thyroid cancer )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>